clinical trial · NCT05297890
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
Advanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerLorlatinib
brief summary
A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib Monotherapy in Crizotinib and Platinum-based Chemotherapy Treated Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)Subjects in China
started
May 27, 2022
primary completion
Dec 26, 2023
completion
May 1, 2027
last updated
May 19, 2026
official title
A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib Monotherapy in Crizotinib and Platinum-based Chemotherapy Treated Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer Subjects in China
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol